Neuromodulation to target glucose transporter and/or incretin pathways

Patent metadata

Field	Value
Publication number	US-12336835-B2
Application number	US-202418766198-A
Country	US
Kind code	B2
Filing date	Jul 8, 2024
Priority date	Mar 12, 2019
Publication date	Jun 24, 2025
Grant date	Jun 24, 2025

Abstract

The subject matter of the present disclosure generally relates to techniques for neuromodulation that include applying energy (e.g., ultrasound energy) into the tissue to cause a change in a glucose transporter pathway molecule and/or an incretin pathway molecule. In one embodiment, the neuromodulation is performed as a treatment of a metabolic disorder.

First claim

The invention claimed is:

1. A method for treating a subject having a metabolic disorder, comprising:
identifying within image data a first region of interest on a first organ and a second region of interest on a second organ;
applying ultrasound energy to the first region of interest to cause a change in glucose absorption of a subject; and
applying ultrasound energy to the second region of interest to cause a change in glucose excretion of the subject, wherein a balance between glucose absorption and glucose excretion is changed in a therapeutic manner by applying ultrasound energy to the first region of interest and the second region of interest.

2. The method of claim 1 , wherein the change in glucose absorption is associated with a change in concentration of one or more of SGLT1, SGLT2, GLP1, GLUT2, GLUT5, IRS2, or PKC.

3. The method of claim 1 , wherein the change in glucose excretion is associated with a change in concentration of one or more of SGLT1, SGLT2, GLP1, GLUT2, GLUT5, IRS2, or PKC.

4. The method of claim 1 , wherein the first region of interest comprises a region or sub-region of a liver, gastrointestinal (GI) tract, pancreas, or kidney.

5. The method of claim 1 , wherein the second region of interest comprises a region or sub-region of a liver, gastrointestinal (GI) tract, pancreas, or kidney.

6. The method of claim 1 , wherein the change in glucose absorption corresponds to a downregulation of SGLT2 and GLUT2 in the kidney.

7. The method of claim 1 , wherein the change in glucose absorption corresponds to an increase in concentration of one or more molecules relative to a baseline concentration of the one or more molecules, wherein the one or more molecules comprises GLUT2 in the intestine and kidney.

8. The method of claim 1 , wherein the change in glucose absorption corresponds to an increase in concentration of one or more molecules relative to a baseline concentration of the one or more molecules, wherein the one or more molecules comprises GLP1 in the intestine.

9. A system for treating a subject having a metabolic disorder, the system comprising:
an ultrasound energy application device; and
a controller, wherein the controller is configured to communicate with the ultrasound energy application device to cause acts comprising:
identifying, within image data acquired using the ultrasound energy application device, a first region of interest on a first organ and a second region of interest on a second organ;
applying ultrasound energy, via the ultrasound energy application device, to the first region of interest to cause a change in glucose absorption of a subject; and
applying, via the ultrasound energy application device, ultrasound energy to the second region of interest to cause a change in glucose excretion of the subject, wherein a balance between glucose uptake and glucose excretion is changed in a therapeutic manner by applying ultrasound energy to the first region of interest and the second region of interest.

10. The system of claim 9 , wherein the change in glucose absorption is associated with a change in concentration of one or more of SGLT1, SGLT2, GLP1, GLUT2, GLUT5, IRS2, or PKC.

11. The system of claim 9 , wherein the change in glucose excretion is associated with a change in concentration of one or more of SGLT1, SGLT2, GLP1, GLUT2, GLUT5, IRS2, or PKC.

12. The system of claim 9 , wherein the first region of interest comprises a region or sub-region of a liver, gastrointestinal (GI) tract, pancreas, or kidney.

13. The system of claim 9 , wherein the second region of interest comprises a region or sub-region of a liver, gastrointestinal (GI) tract, pancreas, or kidney.

14. The system of claim 9 , wherein the balance between glucose uptake and glucose excretion corresponds to an increase in concentration of GLUT2 in the liver.

15. A non-transitory, computer-readable medium comprising computer-executable instructions that, when executed by at least one processor, are configured to cause the at least one processor to perform operations comprising:
identifying, within image data acquired using an ultrasound energy application device, a first region of interest on a first organ and a second region of interest in a second organ;
applying, via the ultrasound energy application device, ultrasound energy to the first region of interest to cause a change in glucose absorption of a subject; and
applying, via the ultrasound energy application device, ultrasound energy to the second region of interest to cause a change in glucose excretion of the subject, wherein a balance between glucose uptake and glucose excretion is changed in a therapeutic manner by applying ultrasound energy to the first region of interest and the second region of interest.

16. The non-transitory, computer-readable medium of claim 15 , wherein the change in glucose absorption is associated with a change in concentration of one or more of SGLT1, SGLT2, GLP1, GLUT2, GLUT5, IRS2, or PKC.

17. The non-transitory, computer-readable medium of claim 15 , wherein the change in glucose excretion is associated with a change in concentration of one or more of SGLT1, SGLT2, GLP1, GLUT2, GLUT5, IRS2, or PKC.

18. The non-transitory, computer-readable medium of claim 15 , wherein the change in glucose excretion in the subject corresponds to a downregulation of protein kinase C (PKC), SGLT2, GLUT2, or RS2.

19. The non-transitory, computer-readable medium of claim 15 , wherein the change in glucose absorption corresponds to a downregulation of protein kinase C (PKC), SGLT2, GLUT2, or IRS2.

20. The non-transitory, computer-readable medium of claim 15 , wherein the change in glucose absorption corresponds to a downregulation of SGLT2 and GLUT2 in the kidney.

Assignees

• Ge Prec Healthcare Llc

Inventors

• Cotero Victoria Eugenia
• Puleo Christopher Michael
• Graf John Frederick

Classifications

• G01N33/6872 Primary

  Intracellular protein regulatory factors and their receptors, e.g. including ion channels · CPC title

• G01N33/66

  involving blood sugars, e.g. galactose · CPC title

• A61N2007/0026

  Stimulation of nerve tissue · CPC title

• A61N7/00

  Ultrasound therapy (lithotripsy A61B17/22, A61B17/225; massage using supersonic vibration A61H23/00 {; using ultrasound for introducing media into the body A61M37/0092}) · CPC title

• A61B5/4848

  Monitoring or testing the effects of treatment, e.g. of medication · CPC title